- Open Access
SWATH-MS based quantitative proteomics analysis reveals that curcumin alters the metabolic enzyme profile of CML cells by affecting the activity of miR-22/IPO7/HIF-1α axis
- Francesca Monteleone†1,
- Simona Taverna†2,
- Riccardo Alessandro1, 2Email author and
- Simona Fontana1Email author
© The Author(s). 2018
- Received: 29 January 2018
- Accepted: 13 July 2018
- Published: 25 July 2018
Chronic myelogenous leukemia (CML) is a myeloproliferative disorder caused by expression of the chimeric BCR-ABL tyrosine kinase oncogene, resulting from the t(9;22) chromosomal translocation. Imatinib (gleevec, STI-571) is a selective inhibitor of BCR-ABL activity highly effective in the treatment of CML. However, even though almost all CML patients respond to treatment with imatinib or third generation inhibitors, these drugs are not curative and need to be taken indefinitely or until patients become resistant. Therefore, to get a definitive eradication of leukemic cells, it is necessary to find novel therapeutic combinations, for achieving greater efficacy and fewer side effects.
Curcumin is an Indian spice with several therapeutic properties: anti-oxidant, analgesic, anti-inflammatory, antiseptic and anti-cancer. In cancer disease, it acts by blocking cell transformation, proliferation, and invasion and by inducing cell apoptosis.
In the present study, the effect of a sub-toxic dose of curcumin on K562 cells was evaluated by using the technique of Sequential Window Activation of All Theoretical Mass Spectra (SWATH-MS). Bioinformatic analysis of proteomic data was performed to highlight the pathways mostly affected by the treatment. The involvement of Hypoxia inducible factor 1 α (HIF-1α) was assayed by evaluating its activation status and the modulation of importin 7 (IPO7) and miR-22 was assessed by quantitative PCR and western blot analysis. Finally, K562 cells transfected with miR-22 inhibitor were used to confirm the ability of curcumin to elicit miR-22 expression.
Our findings revealed that the most relevant effect induced by curcumin was a consistent decrease of several proteins involved in glucose metabolism, most of which were HIF-1α targets, concomitant with the up-regulation of functional and structural mitochondrial proteins. The mechanism by which curcumin affects metabolic enzyme profile was associated with the reduction of HIF-1α activity, due to the miR-22-mediated down-regulation of IPO7 expression. Finally, the ability of curcumin to enhance in vitro the efficiency of imatinib was reported.
In summary, our data indicates that the miR-22/IPO7/HIF-1α axis may be considered as a novel molecular target of curcumin adding new insights to better define therapeutic activity and anticancer properties of this natural compound. The MS proteomic data have been deposited to the ProteomeXchange with identifier <PXD007771>.
- CML cells
- miR-22/IPO7/HIF-1α axis
Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm marked by the presence of shortened Philadelphia chromosome (Ph) that results from a reciprocal translocation between chromosome 9 and chromosome 22 [(9;22) (q34;q11)]. The molecular consequence of this translocation is the generation of BCR-ABL fusion oncogene. The protein encoded by this fusion gene is the constitutively active tyrosine kinase BCR-ABL, which drives the malignant process in CML cells and represents the primary target of therapy .
Although the tyrosine kinase inhibitors (TKI) as imatinib mesylate (imatinib, Gleevec) or third generation inhibitors, are effective in controlling CML and preventing progression to blast crisis, they are not curative. Indeed, BCR-ABL transcript can be detected in patients who achieve complete cytogenetic responses , and the cessation of TKI therapy may result in disease relapse also in patients with undetectable level of BCR-ABL transcript . These effects are due to the incapability of TKIs to eliminate leukemia stem cells (LSCs) whose survival is probably supported by kinase-independent pathways . Several experimental evidences highlighted that the upregulation of hypoxia-inducible factor 1 α (HIF-1α) supports LSCs maintenance and potency [4–7], thus indicating that the identification of new drugs targeting HIF-1α may be crucial for developing combined therapeutic strategies to effectively treat patients with CML.
A high number of preclinical studies have shown the relevant role that natural compounds can have in cancer prevention as well as, if used in tandem with conventional therapy, in cancer treatment . Among these natural agents, curcumin, a natural polyphenol compound extracted from the rhizome of Curcuma longa, is reported to inhibit tumor growth through regulating multiple signaling pathways involved in cell proliferation, survival, apoptosis, inflammation and angiogenesis .
In our previous papers we demonstrated that curcumin treatment of CML cells caused a selective sorting of active miR-21 in exosomes and a concomitant decrease of this miRNA in the cells thus leading to the upregulation of PTEN that in turn caused a decrease of AKT phosphorylation and VEGF expression and release. Furthermore, we showed that addition of curcumin to CML cells caused a downregulation of BCR-ABL expression through the cellular increase of miR-196b. Moreover, we observed that animals treated with curcumin, developed smaller tumors compared to control mice and that exosomes isolated from their plasma were enriched in miR-21 [10, 11].
In this study, we employed the proteomic quantitative analytic method SWATH (Sequential Window Acquisition of all THeoretical fragment-ion spectra)  to examine how curcumin affected the protein profile of K562 cells. Our findings revealed that curcumin treatment, in CML cells, induced an increase of several mitochondrial structural and functional proteins and a simultaneous consistent decrease of several proteins involved in glucose metabolism, most of which were HIF-1α targets. According to this observation, we found that curcumin was able induce a significant reduction of HIF-1α activity in comparison to untreated K562 cells. Moreover, the bioinformatics analysis of protein-expression data allowed us to identify miR-22 and its target Importin 7 (IPO7) as possible molecular mediators of the effects observed in curcumin-treated CML cells. Our findings reveal the ability of curcumin to up-regulate the expression levels of miR-22 and down-regulate the IPO7 expression, thus affecting the cytoplasm-to-nucleus shuttling of HIF-1α. We also demonstrated that the curcumin-induced up-regulation of miR22 may increase the intrinsic imatinib sensitivity of K562 cells, providing new insights for reducing excessive side effects in patients using the current fixed dosing strategy.
Cell culture, reagents and treatments
The human CML cell lines K562 and LAMA84 (DSMZ, Braunschweig, Germany) were cultured in RPMI 1640 medium (Euroclone, UK), supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin (Euroclone, UK).
Imatinib (Selleck) was prepared as 5 mM stock solution in sterile phosphate-buffered saline (PBS); curcumin was prepared as 100 mM stock solution in 0.1% DMSO; working solutions of both curcumin and imatinib were performed in culture medium the same day of use. For the following experiments cells were treated with 20 μM curcumin (Curcu-K562) and/or escalating doses of imatinib (Im-K562) for 24 h. In the assays with curcumin, control cells (Ctrl-K562) were treated with DMSO percentage used in working solution (Ctrl-K562).
All other reagents were purchased from Sigma (St. Louis, MO), if not otherwise cited.
Proteomic analyses: Sample preparation, SWATH-MS and data analysis
Protein extraction and digestion
Chemicals used for protein extraction and digestion were of analytical grade, and Milli-Q water was employed in all buffers and solutions. K562 treated with only DMSO or with 20 μM of curcumin (respectively Ctrl-K562 and Curcu-K562) were lysed in RIPA buffer (NaCl 5 M, Tris HCl pH 7.6 1 M, 5% Triton X-100) containing protease and phosphatase inhibitors for 90 min in ice; lysates were centrifuged at 14000 g for 12 min at 4 °C and protein concentration was determined by Bradford method. Before performing tryptic digestion, 250 μg of each cell lysate were precipitated using the 2-D Clean-Up Kit (Amersham) to remove Triton and other contaminants used for cell lysis; purified proteins were suspended buffer containing Tris HCl (100 mM) and urea (8 M) and subjected to in-solution digestion. Reduction was performed with 2 mM DTT for 30 min at 37 °C and alkylation with 8 mM IAA for 30 min in the dark at 37 °C. Prior to trypsin addition, sample was diluted with five-volumes of 100 mM NH4HCO3 pH 8.5. Proteins were digested using 4 μg of sequencing-grade modified porcine trypsin (Pierce) (1:60, w/w, trypsin to protein ratio), in presence of 2 mM CaCl2. After overnight incubation, digestion was stopped by adding 50 μl of 2.5% trifluoroacetic acid (TFA). Once concentrated with a speed vacuum centrifuge, before injection, extracted peptides were desalted by solid phase extraction using C18 Macrospin Columns. C18 columns were conditioned with acetonitrile (ACN) and rinsed with water; peptides were eluted with 70% ACN/H2O (70:30, v/v) containing 0.1% formic acid (FA), and were dried, to be then re-suspended in 5% ACN/H2O (5:95, v/v) containing 0.1% FA. For each sample, two biological replicates were prepared and used for the following proteomic analysis.
Generation of the reference spectral library
Approximately 2 μg of pooled tryptic peptides from each biological replicate of Ctrl-K562 and Curcu-K562 were subjected to Data Dependent Acquisition (DDA) analysis. The resulting list of protein/peptides was used for construction of the SWATH reference spectral library. The sample was analyzed via reverse-phase high-pressure liquid chromatography electrospray ionization tandem mass spectrometry (RP-HPLC-ESI-MS/MS) using a TripleTOF® 5600 mass spectrometer (AB SCIEX; Framingham, US). The mass spectrometer was coupled to a nanoLC Eksigent 425 system (AB SCIEX; Framingham, US). RP-HPLC was performed with a trap and elution configuration using a Nano cHiPLC Trap column 200 μm × 0.5 mm ChromXP C18-CL 3 μm 120 Å and a Nano cHiPLC column 75 μm × 15 cm ChromXP C18-CL 3 μm 120 Å. The reverse-phase LC solvents were: solvent A (0.1% formic acid in water) and solvent B (2% water and 0.1% formic acid in acetonitrile). The sample was loaded in the trap column at a flow rate of 5 μl/min for 10 min in a solvent containing 2% acetonitrile and 0.1% v/v TFA in water and eluted at a flow rate of 300 nl/min using the following gradient method: 1) solvent B from 10 to 28% within 120 min and to 60% within 30 min; 2) phase B to 95.2% within 2 min; 3) phase B decreased to 94.8% for 10 min (to rinse the column); 4) phase B decreased to 10% over 2 min. Finally, the column was equilibrated for 36 min (200 min total run time). The eluting peptides were on-line sprayed in the Triple TOF 5600 Plus mass spectrometer, that it is controlled by Analysts 1.6.1 software (AB SCIEX, Toronto, Canada).
For DDA run, the mass range for MS scan was set to m/z 350–1250 and the MS/MS scan mass range was set to m/z 230–1500. Using the mass spectrometer, a 0.25 s survey scan (MS) was performed, and the top 25 ions were selected for subsequent MS/MS experiments employing an accumulation time of 0.15 s per MS/MS experiment for a total cycle time of 4.0504 s. Precursor ions were selected in high resolution mode (> 30,000), tandem mass spectra were recorded in high sensitivity mode (resolution > 15,000). The selection criteria for parent ions included an intensity of greater than 50 cps and a charge state ranging from + 2 to + 5. A 15 s dynamic exclusion was used. The ions were fragmented in the collision cell using rolling collision energy, and CES was set to 2.
The DDA MS raw file was subjected to database searches using ProteinPilot™ 4.5 software (AB SCIEX; Framingham, US) with the Paragon algorithm by using the following parameters: iodoacetamide cysteine alkylation, digestion by trypsin and no special factors. The search was conducted through identification efforts in a UniProt database (downloaded in July 2014, with 137,216 protein sequence entries) containing whole Homo sapiens proteins. A false discovery rate analysis was performed.
SWATH-MS analysis and targeted data extraction
The two biological replicates of Ctrl-K562 and Curcu-K562 (2 μg each) were twice run and subjected to the cyclic data independent acquisition (DIA) of mass spectra. Data were acquired by repeatedly cycling through 34 consecutive 25-Da precursor isolation windows (swaths). For these experiments, the mass spectrometer was operated using a 0.05 s survey scan (MS). The subsequent MS/MS experiments were performed across the mass range of 350 to 1250 m/z on all precursors in a cyclic manner using an accumulation time of 0.0898 s per SWATH window for a total cycle time of 3.3335 s. Ions were fragmented for each MS/MS experiment in the collision cell using rolling collision energy, and CES was set to 15. Spectral alignment and targeted data extraction of DIA data files were performed with PeakView v.2.2 SWATH Processing MicroApp v2.0 (AB SCIEX; Framingham, US) by using the reference spectral library generated as above described. All eight DIA files were loaded in one comparison group in unison and processed as reported by Li H. et al.  with the following modifications: up to ten peptides/protein and up to seven transitions/peptide. The area under the intensity curve for individual ions of a targeted peptide were summed to represent the peptide and the areas of the corresponding peptides were summed to represent the targeted proteins. These areas were used for relative quantification and statistics analysis. For each protein, seven individual ion intensities were summed for obtaining peptide intensity, ten peptides intensities were summed for obtaining protein intensity. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org)  via the PRIDE partner repository  with the dataset identifier <PXD007771>.
Statistical analysis, gene ontology analysis, functional networks and pathway mapping
The protein list with FDR lower than 5% generated by analyzing SWATH data with PeakView 2.2, was exported to MarkerView 1.2.1 (AB SCIEX; Framingham, US) for normalization of protein intensity (peak area) using the total area sums algorithm and t-test analysis [13, 16]. Mean of all biological and technical replicates was used to compare proteins of Ctrl-K562 and Curcu-K562. Fold Change (FC) Curcu-K562 vs Ctrl-K562 thresholds at ±1.5 with a corrected p-value inferior to 0.05 were used to consider a protein up or down-regulated. GraphPad Prism 7.00 for Windows was used for (i) performing the p-value Benjamini-Yekutieli (BY-Pvalue) correction (13); (ii) to make a volcano plot scaling in which the FC was transformed using the log2 function, so that the data is centered on zero, while the BY corrected p-value was −log10 transformed. The Graphical Proteomics Data Explorer (GProX), a freely available complete software platform (14) was used to calculate the linear regression of repeats. The analysis of coefficients of variation for replicates was performed using Microsoft Excel 2010. The expression-based heat map was obtained by using the Heatmapper freely available web server (http://www.heatmapper.ca). The Gene Ontology (GO) and KEGG (Kyoto Encyclopedia of Genes and Genomes) analysis of proteins up- and down-regulated following treatment with curcumin (respectively Curcu-UpRegProteins and Curcu-DownRegProteins) were initially performed using the stand-alone enrichment analysis tool FunRich (Functional Enrichment analysis tool; http://www.funrich.org) . The ClueGO v2.3.3 + CluePedia v1.3.3, a Cytoscape v3.4.0 plug-in was used to visualize the non-redundant GO terms and pathways in functionally organized networks reflecting the relations between the biological terms based on the similarity of their linked gene/proteins . In order to make cluster/group comparison and highlight functional differences, the two protein groups mentioned above were uploaded in ClueGO as two separate clusters using the Cytoscape environment .
For the enrichment of biological terms and groups, we used the two-sided (Enrichment/Depletion) tests based on the hyper-geometric distribution. We set the statistical significance to 0.05 (p ≤ 0.05), and we used the Benjamini-Hochberg adjustment to correct the p-value for the terms and the groups created by ClueGO. We used fusion criteria to diminish the redundancy of the terms shared by similar associated proteins, which allows one to maintain the most representative parent or child term and the used parameters were: kappa score threshold set to 0.4; GO tree interval: 3–8; GO Term Fusion; Leading Group: Highest Significance; % of Group Merge: 50.
Quantitative polymerase chain reaction (qPCR) for miR-22
The expression of miR-22 was tested by miScript PCR System (QIAGEN, Hilden, Germany). The RNAspin Mini (GE Healthcare Science, Uppsala, Sweden) was used to isolate total RNA from K562 and LAMA84 cells treated or not with curcumin. Reverse transcription reactions were performed using miScript II RT Kit (QIAGEN, Hilden, Germany) as described by the manufacturer’s instructions. We used miScript HiSpec Buffer for cDNA synthesis to detect mature miRNA. Quantitative Real Time PCR was performed using miScript SYBR Green PCR Kit (QIAGEN, Hilden, Germany). Mature miR-22-3p (mature miRNA sequence 5’-AAGCUGCCAGUUGAAGAACUGU-3′) was detected by miScript Primer Assay (MIMAT0000077; QIAGEN, Hilden, Germany) according to manufacturer’s instructions. RNU6–2 was used as endogenous control. Expression levels of miRNAs were determined using the comparative Ct method to calculate changes in Ct and ultimately fold and percent change. An average Ct value for each RNA was obtained from triplicate reactions.
qPCR for HIF-1α and IPO7
Total cellular RNA was isolated from K562 and LAMA84 cells treated with curcumin using the RNAspin Mini (GE Healthcare Science, Uppsala, Sweden). For HIF-1α and Importin 7 (IPO7) mRNA detection, 1 μg of total RNA was reverse transcribed using the High Capacity cDNA Archive kit (Life Technologies, Carlsbad, California, U.S.), according to manufacturer’s instructions. HIF-1α and IPO7 transcript levels were measured by quantitative SYBER®Green real time PCR; reactions were carried out in a total volume of 20 μl containing 2× SYBR®Green I Master Mix (Applied Biosystems), 2 μl cDNA and 300 nM forward and reverse primers. Primers sequence were: GAPDH (5′ATGGGGAAGGTGAAGGTCG3′; 5′GGGTCATTGATGGCAACAATAT3′), HIF-1α (5’ TGATTGCATCTCCATCTCCTACC3’; 5’GACTCAAAGCGACAGATAACACG3’) and IPO7 (5’TGGGACCTGATCATGCAACC3’; 5’AGCTGCCTTCATGACATCCC3’). All reagents were from Invitrogen (Foster City, CA, USA). Real-time PCR was performed in duplicates for each data point. Relative changes in gene expression between control and treated samples were determined with the ΔΔCt method. Changes in the target mRNA content relative to GAPDH were determined using the comparative Ct method as described in the previous paragraph.
Transfection of K562 cells with miR-22 inhibitor
Transfection of miScript miR-22-3p inhibitor (MIN0000077, QIAGEN, Hilden, Germany) in K562 cells (QIAGEN, Hilden, Germany) was performed according Fast-Forward Transfection protocol (QIAGEN, Hilden, Germany). 6 × 104 K562 cells per well were seeded in a 24-well plate in 500 μl of RPMI. miScript miR-22 (2’-O-Me-miR-22) (2 μM) were diluted in 100 μl culture medium without serum to obtain a final 5 nM miRNA concentration. The cells were transfected using HiPerFect Transfection Reagent (QIAGEN, Hilden, Germany) according to manufacturer’s instructions for 18 h. MiScript Inhibitor Negative Control (QIAGEN, Hilden, Germany) was used as negative control as indicated by manufacture’s technical specifications. Transfection efficiency was evaluated by quantitative Real Time PCR.
HIF1α transcription activation assay
K562 and LAMA84 cells treated with 20 μM of curcumin were harvested after 24 h of incubation. K562 cells were also transfected or not with miR-22 inhibitor. Nuclear extracts were prepared by using the Nuclear Extract Kit from Activemotif (#40010 - Activemotif, Carlsbad, CA, USA) according to the manufacturer’s instructions. The transcriptional activity of HIF-1α was assayed by an ELISA-based kit (#47096 - TransAM Kit, Activemotif, Carlsbad, CA, USA) according to the manufacturer’s instructions. Nuclear extract samples were added to the coated plate and analyzed at 450 nm with Gen5 Microplate Collection & Analysis Software Data (BioTek Instruments, Inc.®). HIF-1α activity was expressed as Absorbance value.
Total cell lysates or nuclear/cytoplasm fractions were resolved in 6 or 8% SDS-PAGE and analyzed by Western Blot. Primary antibodies used in the experiments were: anti-IPO7 (1:500; ThermoFischer), anti-HIF-1α (1:1000; Millipore) and anti-actin beta (1:500; Cell Signaling Technology, Beverly, MA). Secondary antibodies (anti-mouse or anti-rabbit depending on primary antibody) were Alexa Fluor or HRP conjugated. When HRP conjugated secondary antibodies were used, protein bands were detected using Amersham ECL Western Blotting Detection Reagent; protein bands were finally visualized using Chemidoc (BioRad). The signal intensity of each band was calculated with Image J software (http://rsbweb.nih.gov/ij/).
Proliferation assay (MTT assay)
Methyl-thiazol-tetrazolium (MTT) assay was done as previously described [20, 21]. K562 and LAMA84 cells were seeded in 96-well plates (2–5 × 103 cells/well) and incubated for 24 h with 10, 20, 40 μM curcumin for 24 h.
For co-treatment experiments, K562 cells were seeded in 96-well plates (2–5 × 103 cells/well) and incubated for 24 h with 20 μM curcumin (Curcu-K562) and/or escalating doses of imatinib (Im-K562). In order to assess the synergism between curcumin and imatinib on viability, both K562 and LAMA84 cells were treated for 48 h with curcumin alone (5, 10, 20, 40, 50 μM), imatinib alone (0.1, 0.2, 0.5, 1 and 5 μM) or imatinib + curcumin combination (imatinib at concentrations of 0.1, 0.2, 0.5, 1 and 5 μM; 20 μM curcumin held constant). Cell proliferation was assessed using a MTT assay. Control cells were seeded in absence of curcumin and with appropriate percentage of DMSO. Means and standard deviations were generated from three independent experiments. Graphs and statistical analysis were performed by using Microsoft Excel 2010. For synergism determination, percent cell survival results were converted to Fraction Affected (FrAf) as follows: FrAf = 0 represents 100% viability; FrAf = 1 represents 0% viability. Imtinib + curcumin interaction was assessed by Combination Index (CI) analysis using the CompuSyn software program (ComboSyn, Inc., Paramus, NJ) based on the Chou-Talalay equation [22, 23]. CI index of less than 1 was considered to indicate a synergistic interaction.
Summary of protein identification results
Numbers of proteins in DDA protein library
Numbers of peptides in DDA protein library
Numbers of proteins quantified in SWATH analysis
Numbers (and percentage) of quantified protein with CV ≤ 25% among technical and biological replicates
Bioinformatic analysis for enriched terms
Most significantly enriched GO categories (adjP ≤10−5) within the differentially Curcu-regulated proteins datasets
# of proteins in the dataset (a)
# of proteins in the background dataset (b)
% of proteins
AdjP-Value (BH method)
Cellular Component (CC)
Enriched in Curcu-Down-Regulated protein dataset
Proteasome regulatory particle
Enriched in Curcu-Up Regulated protein dataset
Mitochondrial respiratory chain complex I
Mitochondrial inner membrane
Mitochondrial respiratory chain
Mitochondrial outer membrane translocase complex
Molecular Function (MF)
Enriched in Curcu-Down-Regulated protein dataset
Ubiquitin-specific protease activity
Translation regulator activity
Enriched in Curcu-Up Regulated protein dataset
Biological Process (BP)
Enriched in Curcu-Down Regulated protein dataset
Enriched in Curcu-Up Regulated protein dataset
We found that most of the proteins down-regulated by curcumin treatment were associated with cytosolic localization (Fig. 3 histogram “CC”: Cytoplasm, Cytosol, Proteasome complex, Cytoskeleton, Microtubule, Proteasome regulatory particle. See Table 2 for the details of this analysis) and cytosolic functions (Fig. 3 histogram “MF”: Chaperone activity, Ubiquitin-specific protease activity, Translation regulator activity, Isomerase activity; Fig. 3 histogram “BP”: Protein metabolism. See Table 2 for the details of this analysis), while the group of proteins up-regulated by curcumin treatment were significantly enriched in the categories associated with mitochondrial localization (Fig. 3 histogram “CC”: Mitochondrion and 5 categories related to mitochondrial membrane localization. See Table 2 for the details of this analysis) and mitochondrial activities (Fig. 3 histogram “MF”: Oxidoreductase activity; Fig. 3 histogram “BP”: Transport. See Table 2 for the details of this analysis).
Biological Pathway enrichment analysis of “metabolic” proteins down-regulated and up-regulated by curcumin
% of proteins
AdjP-Value (BH method)
Curcu-Down-Regulated “metabolic” proteins
TALDO1; ARG2; GSTP1; AHCY; TXN; FASN; TKT; COX6B1; GMPS; PAICS; HPRT1; CAD; ATIC; GSTO1; ACLY; GOT1; TK1;
Metabolism of carbohydrates
TPI1; TALDO1; GPI; MDH1; PGK1; TKT; PGD; GOT1;
TPI1; GPI; MDH1; PGK1; GOT1;
TPI1; GPI; MDH1; PGK1; GOT1;
TPI1; GPI; PGK1;
Cytosolic tRNA aminoacylation
DARS; PPA1; VARS; YARS;
HIF-1-alpha transcription factor network
ALDOA; PKM; LDHA; PGK1;
Pentose phosphate pathway (oxidative branch)
Curcu-Up-Regulated “metabolic” proteins
Respiratory electron transport
UQCRC1; CYC1; COX5B; NDUFS1; NDUFA5; NDUFB4; NDUFV1; UQCRH; NDUFA9; UQCRB; MT-ND5; NDUFB6; NDUFB5; NDUFB3; NDUFB9;
The citric acid (TCA) cycle and respiratory electron transport
UQCRC1; CYC1; COX5B; NDUFS1; NDUFA5; NDUFB4; NDUFV1; UQCRH; NDUFA9; UQCRB; MT-ND5; NNT; NDUFB6; NDUFB5; NDUFB3; NDUFB9;
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.
UQCRC1; CYC1; COX5B; NDUFS1; NDUFA5; NDUFB4; NDUFV1; UQCRH; NDUFA9; UQCRB; MT-ND5; NDUFB6; NDUFB5; NDUFB3; NDUFB9;
UQCRC1; CYC1; COX5B; NDUFS1; NDUFA5; NDUFB4; NDUFV1; CYP51A1; UQCRH; NDUFA9; UQCRB; MT-ND5; NNT; NDUFB6; NDUFB5; NDUFB3; NDUFB9;
FDFT1; CYP51A1; DHCR24;
Effects of curcumin on HIF-1α activity and IPO7 expression
Proteins implicated in nuclear import/export identified by MS in K562cells
UniProt Accession Number
UniProt Entry Name
Fold Change (Curcu-K562 vs Ctrl K562)
Importin subunit alpha-1
Importin subunit alpha-3
Importin subunit alpha-4
Importin subunit beta-1
Nuclear pore complex protein Nup50
Analogous effects of curcumin treatment on HIF-1α expression and activity as well as on IPO7 expression were also observed in LAMA84 cells (Additional file 9: Figure S4a-d).
Interestingly, we found that in both K562 and LAMA84 cells the down-regulation of HIF-1α activity induced by curcumin coincided with its reduced nuclear localization (Additional file 10: Figure S5).
Curcumin inhibits IPO7 expression through the activation of miR-22
Analogous effect of curcumin treatment on miR-22 expression was observed in LAMA84 cells (Additional file 9: Figure S4e).
Curcumin enhances the sensitivity of K562 cells to imatinib
Nutraceuticals play an increasingly important role in the cancer management . Among them curcumin, a natural polyphenol extracted from Curcuma longa L., has been shown to have pleotropic anti-cancer properties (anti-oxidant, anti-inflammatory, anti-proliferative) inhibiting multiple targets and molecular pathways such as NF-kB, STAT3, MAPK, PTEN, P53, AKT/mTOR, VEGF and microRNAs (miRNA) network involved in cancer pathogenesis [9, 11, 34, 35]. Data accumulated in the last years has revealed that curcumin is a promising pharmacologically safe anti-tumor agent that can function as chemosensitizer and a multi-targeted inhibitor. However, actually the use of curcumin as therapeutic remedy is strongly limited by its extremely low solubility in water and in organ fluids, which subsequently limits the bioavailability and therapeutic effects of curcumin. Currently, continuous attempts are going to improve solubilization and bioavailability of this promising agent. For example it has been demonstrated that heat and pressure can significantly improve solubility of curcumin maintaining its therapeutic properties [36–39].
The benefits of curcumin have been demonstrated also in blood cancer. In acute lymphoblastic leukemia Philadelphia chromosome-positive (Ph + ALL), it was demonstrated that curcumin potentiated the efficiency of imatinib by inhibiting the activation of the AKT/mTOR signaling and by down-regulating the expression of the BCR/ABL gene . Similarly in CML it was demonstrated that curcumin treatment induced the decrease of BCR-ABL expression at both mRNA and protein level associated to a dose-dependent increase of PTEN and a decreased AKT phosphorylation and VEGF expression due to a selective packaging of miR-21 in exosomes .
In the present study, for the first time, we demonstrated that in CML cells curcumin at sub toxic dose affects the HIF-1α pathway that it is known to promote leukemic cell proliferation and to play a key role in the progressive loss of sensitivity to imatinib [5–7].
We have applied SWATH-MS (sequential window acquisition of all theoretical spectra-mass spectrometry)-based quantitative proteomic analysis to examine the effect of curcumin on proteome of K562 cells, that our previous data indicated to have an intrinsic resistance to imatinib, likely related to the expression of several proteins implicated in drug resistance and with anti-apoptotic activity . We found that in CML cells curcumin induced, compared to the untreated condition, a remarkable down-regulation of proteasome activity, as described in literature [42, 43], and of proteins associated to carbohydrate metabolism. In particular, we found that several enzymes involved in glycolysis/gluconeogenesis (TPI1; GPI; MDH1; PGK1; GOT1), in oxidative branch of pentose phosphate pathway (G6PD; PGD) and some direct targets of HIF-1α (ALDOA; PKM; LDHA; PGK1) were down-regulated in response to curcumin treatment. The dependence of cancer cells on glycolysis process for energy production rather than oxidative phosphorylation, is so frequent and common in majority, if not, all types of tumors, to be considered as a molecular signature of cancer [44–46]. This tumor glycolysis, associated to more aggressive tumor phenotype, is directly controlled by major signal transduction pathways involved in oncogenesis often associated with HIF-1α activity [47, 48]. In CML cells, in particular, increased glycolytic activity has been found to depend on the non-hypoxic activation of HIF-1α and has been described as marker for early detection of imatinib resistance, before clinical manifestations [7, 49]. Moreover, data from literature has provided strong evidence in support of the crucial role of HIF-1α in the pathogenesis of CML, by promoting cell proliferation and survival maintenance of LSCs [5–7]. Thus, the co-suppression of BCR-ABL and HIF-1α can offer the opportunity to develop a rational therapeutic strategy for CML eradication.
Consistent with the obtained proteomic data evidencing the down-regulation of several HIF-1α targets and associated pathways, we found that in K562 cells curcumin induced a decrease of HIF-1α activity. Previous studies have demonstrated that the anti-cancer properties of curcumin may be related to its ability to affect the HIF-1 pathway, affecting the expression of HIF-1α or by degrading ARNT (HIF1β) but without altering the expression and the transcriptional activity of HIF-1α [50, 51]. Interestingly, in the present study we found that in CML cells curcumin induced a significant inhibition of HIF-1α activity, without affecting its expression. These observations led us to hypothesize that curcumin could have an indirect effect on HIF-1α.
Data from literature reported that curcumin is able to affect nuclear traffic by inhibiting CRM1 (exportin1 or Xpo1) , that we also found down-regulated in curcumin-treated K562 cells together with other proteins implicated in nuclear import/export (in total 14 of these proteins were identified in our dataset). Interestingly among them there was IPO7, an importin specifically related to HIF-1α nuclear translocation . According to literature data strongly supporting the ability of curcumin to regulate miRNA expression [11, 26, 31, 33, 34], we found that in K562 cells the curcumin-dependent down-regulation of IPO7 was miR-22-mediated. To deeper define the molecular steps through which the HIF-1α/miR22/IPO7 axis mediates the curcumin effects on CML cells future research can be aimed to define the timing in which HIF-1α nuclear localization is modulated as well as to identify other interactors acting within this system.
Evidence accumulated in recent years has defined the key role of nuclear transport in regulating the features of cancer cells and highlighted the potential role of nuclear transport proteins as new therapeutic targets for developing combination treatment strategies . For example, the ability of XPO1 inhibitors to enhance the therapeutic effects of some available chemotherapeutic agents used for treating both haematological and solid tumours was reported [53–55]. Interestingly, we found that through its miR-22-mediated activity, curcumin on K562 cells enhanced the anti-proliferative effects of imatinib. This finding adds new evidence about the molecular mechanisms through which curcumin can enhance the efficacy of anti-cancer drugs working as chemosensitizer [43, 56, 57]. From a clinical point of view this is an interesting data since it is widely recognized that during treatment with imatinib, dose optimization proved an effective tool to reach adequate response by improving efficacy and reducing toxicity and costs of treatment .
Our study, for the first time, suggests the miR-22/IPO7/HIF-1α axis as new molecular target of curcumin, revealing innovative therapeutic implications of this natural compound for treatment of CML as well as of other cancer types in which HIF-1α has a prominent role.
This work was supported by a grant from the Associazione Italiana per la Ricerca sul Cancro (AIRC) to R.A; FFR from the University of Palermo to R.A and S.F. This study was also developed with the contribution of National Operational Programme for Research and Competitiveness 2007–2013- PON01_01059 “Sviluppo di una piattaforma tecnologica per il trattamento non invasivo di patologie oncologiche e infettive basate sull’uso di ultrasuoni focalizzati (FUS)”.
Availability of data and materials
All data generated or analysed during this study are included in this published article and its Additional files except the MS proteomic data that have been deposited to the ProteomeXchange with identifier <PXD007771>.
RA and SF conceived and supervised the project; SF, ST, FM and RA contributed to designed and/or interpreted experiments; FM and SF performed the proteomic analysis; ST conducted the experiments of cell and molecular biology; SF, ST and FM wrote the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343–56.PubMedGoogle Scholar
- Hughes TP, Hochhaus A, Branford S, Muller MC, Kaeda JS, Foroni L, Druker BJ, Guilhot F, Larson RA, O'Brien SG, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon and STI571 (IRIS). Blood. 2010;116:3758–65.View ArticlePubMedPubMed CentralGoogle Scholar
- Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, Blanchet O, Marit G, Gluckman E, Reiffers J, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007;109:58–60.View ArticlePubMedGoogle Scholar
- Ng KP, Manjeri A, Lee KL, Huang W, Tan SY, Chuah CT, Poellinger L, Ong ST. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition. Blood. 2014;123:3316–26.View ArticlePubMedGoogle Scholar
- Chen H, Shen Y, Gong F, Jiang Y, Zhang R. HIF-alpha promotes chronic myelogenous leukemia cell proliferation by upregulating p21 expression. Cell Biochem Biophys. 2015;72:179–83.View ArticlePubMedGoogle Scholar
- Zhang H, Li H, Xi HS, Li S. HIF1alpha is required for survival maintenance of chronic myeloid leukemia stem cells. Blood. 2012;119:2595–607.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhao F, Mancuso A, Bui TV, Tong X, Gruber JJ, Swider CR, Sanchez PV, Lum JJ, Sayed N, Melo JV, et al. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming. Oncogene. 2010;29:2962–72.View ArticlePubMedPubMed CentralGoogle Scholar
- Braicu C, Mehterov N, Vladimirov B, Sarafian V, Nabavi SM, Atanasov AG, Berindan-Neagoe I. Nutrigenomics in cancer: revisiting the effects of natural compounds. Semin Cancer Biol. 2017;46:84–106.View ArticlePubMedGoogle Scholar
- Vallianou NG, Evangelopoulos A, Schizas N, Kazazis C. Potential anticancer properties and mechanisms of action of curcumin. Anticancer Res. 2015;35:645–51.PubMedGoogle Scholar
- Taverna S, Fontana S, Monteleone F, Pucci M, Saieva L, De Caro V, Cardinale VG, Giallombardo M, Vicario E, Rolfo C, et al. Curcumin modulates chronic myelogenous leukemia exosomes composition and affects angiogenic phenotype via exosomal miR-21. Oncotarget. 2016;7:30420–39.PubMedPubMed CentralGoogle Scholar
- Taverna S, Giallombardo M, Pucci M, Flugy A, Manno M, Raccosta S, Rolfo C, De Leo G, Alessandro R. Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia cells growth: a possible role for exosomal disposal of miR-21. Oncotarget. 2015;6:21918–33.View ArticlePubMedPubMed CentralGoogle Scholar
- Gillet LC, Navarro P, Tate S, Rost H, Selevsek N, Reiter L, Bonner R, Aebersold R. Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol Cell Proteomics. 2012;O111(016717):11.Google Scholar
- Li H, Wang Y, Fu Q, Li X, Wu C, Shen Z, Zhang Q, Qin P, Shen J, Xia X. Integrated genomic and proteomic analyses of high-level chloramphenicol resistance in campylobacter jejuni. Sci Rep. 2017;7:16973.View ArticlePubMedPubMed CentralGoogle Scholar
- Deutsch EW, Csordas A, Sun Z, Jarnuczak A, Perez-Riverol Y, Ternent T, Campbell DS, Bernal-Llinares M, Okuda S, Kawano S, et al. The ProteomeXchange consortium in 2017: supporting the cultural change in proteomics public data deposition. Nucleic Acids Res. 2017;45:D1100–6.View ArticlePubMedGoogle Scholar
- Vizcaino JA, Csordas A, del-Toro N, Dianes JA, Griss J, Lavidas I, Mayer G, Perez-Riverol Y, Reisinger F, Ternent T, et al. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res. 2016;44:D447–56.View ArticlePubMedGoogle Scholar
- Gao Y, Wang X, Sang Z, Li Z, Liu F, Mao J, Yan D, Zhao Y, Wang H, Li P, et al. Quantitative proteomics by SWATH-MS reveals sophisticated metabolic reprogramming in hepatocellular carcinoma tissues. Sci Rep. 2017;7:45913.View ArticlePubMedPubMed CentralGoogle Scholar
- Pathan M, Keerthikumar S, Ang CS, Gangoda L, Quek CY, Williamson NA, Mouradov D, Sieber OM, Simpson RJ, Salim A, et al. FunRich: an open access standalone functional enrichment and interaction network analysis tool. Proteomics. 2015;15:2597–601.View ArticlePubMedGoogle Scholar
- Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, Fridman WH, Pages F, Trajanoski Z, Galon J. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009;25:1091–3.View ArticlePubMedPubMed CentralGoogle Scholar
- Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498–504.View ArticlePubMedPubMed CentralGoogle Scholar
- Raimondo S, Naselli F, Fontana S, Monteleone F, Lo Dico A, Saieva L, Zito G, Flugy A, Manno M, Di Bella MA, et al. Citrus Limon-derived nanovesicles inhibit cancer cell proliferation and suppress CML xenograft growth by inducing TRAIL-mediated cell death. Oncotarget. 2015;6:19514–27.View ArticlePubMedPubMed CentralGoogle Scholar
- Corrado C, Raimondo S, Flugy AM, Fontana S, Santoro A, Stassi G, Marfia A, Iovino F, Arlinghaus R, Kohn EC, et al. Carboxyamidotriazole inhibits cell growth of imatinib-resistant chronic myeloid leukaemia cells including T315I Bcr-Abl mutant by a redox-mediated mechanism. Cancer Lett. 2011;300:205–14.View ArticlePubMedGoogle Scholar
- Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440–6.View ArticlePubMedGoogle Scholar
- Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul. 1984;22:27–55.View ArticleGoogle Scholar
- Stelma T, Chi A, van der Watt PJ, Verrico A, Lavia P, Leaner VD. Targeting nuclear transporters in cancer: diagnostic, prognostic and therapeutic potential. IUBMB Life. 2016;68:268–80.View ArticlePubMedGoogle Scholar
- Chachami G, Paraskeva E, Mingot JM, Braliou GG, Gorlich D, Simos G. Transport of hypoxia-inducible factor HIF-1alpha into the nucleus involves importins 4 and 7. Biochem Biophys Res Commun. 2009;390:235–40.View ArticlePubMedGoogle Scholar
- Zhou S, Zhang S, Shen H, Chen W, Xu H, Chen X, Sun D, Zhong S, Zhao J, Tang J: Curcumin inhibits cancer progression through regulating expression of microRNAs. Tumour Biol 2017, 39:1010428317691680.Google Scholar
- Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15–20.View ArticlePubMedGoogle Scholar
- Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell. 2007;27:91–105.View ArticlePubMedPubMed CentralGoogle Scholar
- Szczyrba J, Nolte E, Hart M, Doll C, Wach S, Taubert H, Keck B, Kremmer E, Stohr R, Hartmann A, et al. Identification of ZNF217, hnRNP-K, VEGF-A and IPO7 as targets for microRNAs that are downregulated in prostate carcinoma. Int J Cancer. 2013;132:775–84.View ArticlePubMedGoogle Scholar
- Sibbesen NA, Kopp KL, Litvinov IV, Jonson L, Willerslev-Olsen A, Fredholm S, Petersen DL, Nastasi C, Krejsgaard T, Lindahl LM, et al. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-cell lymphoma. Oncotarget. 2015;6:20555–69.View ArticlePubMedPubMed CentralGoogle Scholar
- Sreenivasan S, Thirumalai K, Danda R, Krishnakumar S. Effect of curcumin on miRNA expression in human Y79 retinoblastoma cells. Curr Eye Res. 2012;37:421–8.View ArticlePubMedGoogle Scholar
- Teiten MH, Dicato M, Diederich M. Curcumin as a regulator of epigenetic events. Mol Nutr Food Res. 2013;57:1619–29.View ArticlePubMedGoogle Scholar
- Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther. 2008;7:464–73.View ArticlePubMedGoogle Scholar
- Mirzaei H, Masoudifar A, Sahebkar A, Zare N, Nahand JS, Rashidi B, Mehrabian E, Mohammadi M, Mirzaei HR, Jaafari MR. MicroRNA: a novel target of curcumin in Cancer therapy. J Cell Physiol. 2017;2233:3004–15.Google Scholar
- Wang X, Hang Y, Liu J, Hou Y, Wang N, Wang M. Anticancer effect of curcumin inhibits cell growth through miR-21/PTEN/Akt pathway in breast cancer cell. Oncol Lett. 2017;13:4825–31.View ArticlePubMedPubMed CentralGoogle Scholar
- Kurien BT, Harris VM, Quadri SM, Coutinho-de Souza P, Cavett J, Moyer A, Ittiq B, Metcalf A, Ramji HF, Truong D, et al. Significantly reduced lymphadenopathy, salivary gland infiltrates and proteinuria in MRL-lpr/lpr mice treated with ultrasoluble curcumin/turmeric: increased survival with curcumin treatment. Lupus Sci Med. 2015;2:e000114.View ArticlePubMedPubMed CentralGoogle Scholar
- Hani U, Shivakumar HG. Solubility enhancement and delivery systems of curcumin a herbal medicine: a review. Curr Drug Deliv. 2014;11:792–804.View ArticlePubMedGoogle Scholar
- Liu W, Zhai Y, Heng X, Che FY, Chen W, Sun D, Zhai G. Oral bioavailability of curcumin: problems and advancements. J Drug Target. 2016;24:694–702.View ArticlePubMedGoogle Scholar
- Kurien BT, Singh A, Matsumoto H, Scofield RH. Improving the solubility and pharmacological efficacy of curcumin by heat treatment. Assay Drug Dev Technol. 2007;5:567–76.View ArticlePubMedGoogle Scholar
- Guo Y, Li Y, Shan Q, He G, Lin J, Gong Y. Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia. Int J Biochem Cell Biol. 2015;65:1–11.View ArticlePubMedGoogle Scholar
- Fontana S, Alessandro R, Barranca M, Giordano M, Corrado C, Zanella-Cleon I, Becchi M, Kohn EC, De Leo G. Comparative proteome profiling and functional analysis of chronic myelogenous leukemia cell lines. J Proteome Res. 2007;6:4330–42.View ArticlePubMedGoogle Scholar
- Milacic V, Banerjee S, Landis-Piwowar KR, Sarkar FH, Majumdar AP, Dou QP. Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res. 2008;68:7283–92.View ArticlePubMedPubMed CentralGoogle Scholar
- Shen M, Chan TH, Dou QP. Targeting tumor ubiquitin-proteasome pathway with polyphenols for chemosensitization. Anti Cancer Agents Med Chem. 2012;12:891–901.View ArticleGoogle Scholar
- Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891–9.View ArticlePubMedGoogle Scholar
- Ganapathy-Kanniappan S. Taming tumor glycolysis and potential implications for immunotherapy. Front Oncol. 2017;7:36.PubMedPubMed CentralGoogle Scholar
- Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21:297–308.View ArticlePubMedPubMed CentralGoogle Scholar
- Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 2008;8:705–13.View ArticlePubMedGoogle Scholar
- Robey IF, Stephen RM, Brown KS, Baggett BK, Gatenby RA, Gillies RJ. Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia. 2008;10:745–56.View ArticlePubMedPubMed CentralGoogle Scholar
- Klawitter J, Kominsky DJ, Brown JL, Christians U, Leibfritz D, Melo JV, Eckhardt SG, Serkova NJ. Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. Br J Pharmacol. 2009;158:588–600.View ArticlePubMedPubMed CentralGoogle Scholar
- Choi H, Chun YS, Kim SW, Kim MS, Park JW. Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition. Mol Pharmacol. 2006;70:1664–71.View ArticlePubMedGoogle Scholar
- Shan B, Schaaf C, Schmidt A, Lucia K, Buchfelder M, Losa M, Kuhlen D, Kreutzer J, Perone MJ, Arzt E, et al. Curcumin suppresses HIF1A synthesis and VEGFA release in pituitary adenomas. J Endocrinol. 2012;214:389–98.View ArticlePubMedGoogle Scholar
- Niu M, Wu S, Mao L, Yang Y. CRM1 is a cellular target of curcumin: new insights for the myriad of biological effects of an ancient spice. Traffic. 2013;14:1042–52.View ArticlePubMedGoogle Scholar
- Turner JG, Dawson J, Cubitt CL, Baz R, Sullivan DM. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol. 2014;27:62–73.View ArticlePubMedGoogle Scholar
- Turner JG, Dawson J, Emmons MF, Cubitt CL, Kauffman M, Shacham S, Hazlehurst LA, Sullivan DM. CRM1 inhibition sensitizes drug resistant human myeloma cells to topoisomerase II and proteasome inhibitors both in vitro and ex vivo. J Cancer. 2013;4:614–25.View ArticlePubMedPubMed CentralGoogle Scholar
- Kazim S, Malafa MP, Coppola D, Husain K, Zibadi S, Kashyap T, Crochiere M, Landesman Y, Rashal T, Sullivan DM, Mahipal A. Selective nuclear export inhibitor KPT-330 enhances the antitumor activity of gemcitabine in human pancreatic Cancer. Mol Cancer Ther. 2015;14:1570–81.View ArticlePubMedPubMed CentralGoogle Scholar
- Goel A, Aggarwal BB. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer. 2010;62:919–30.View ArticlePubMedGoogle Scholar
- Limtrakul P. Curcumin as chemosensitizer. Adv Exp Med Biol. 2007;595:269–300.View ArticlePubMedGoogle Scholar
- Lankheet NAG, Desar IME, Mulder SF, Burger DM, Kweekel DM, van Herpen CML, van der Graaf WTA, van Erp NP. Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. Br J Clin Pharmacol. 2017;83:2195–204.View ArticlePubMedGoogle Scholar